Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RLYB 
Rallybio Corp (RLYB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RLYB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.1% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.64M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 4 | Beta -1.11 | 52 Weeks Range 0.22 - 1.24 | Updated Date 08/29/2025 |
52 Weeks Range 0.22 - 1.24 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.2367 | Actual -0.22 |
Profitability
Profit Margin - | Operating Margin (TTM) -4743.87% |
Management Effectiveness
Return on Assets (TTM) -36.34% | Return on Equity (TTM) -66.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -22282219 | Price to Sales(TTM) 32.38 |
Enterprise Value -22282219 | Price to Sales(TTM) 32.38 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.41 | Shares Outstanding 41786500 | Shares Floating 19859438 |
Shares Outstanding 41786500 | Shares Floating 19859438 | ||
Percent Insiders 4.14 | Percent Institutions 74.65 |
Upturn AI SWOT
Rallybio Corp
Company Overview
History and Background
Rallybio Corp. is a clinical-stage biotechnology company focused on identifying and developing therapies for patients with rare diseases. Founded in 2018, the company has rapidly advanced its pipeline, focusing on hematology, immuno-inflammation, and metabolism.
Core Business Areas
- Hematology: Developing therapies for rare hematologic disorders, focusing on complement-mediated diseases and other blood-related conditions.
- Immuno-Inflammation: Developing therapies for rare autoimmune and inflammatory diseases, targeting specific pathways to modulate immune responses.
- Metabolism: Developing therapies for rare metabolic disorders, addressing unmet needs in this area.
Leadership and Structure
The company is led by a team of experienced biotech executives, including Martin Mackay, PhD, as CEO. The organizational structure is designed to support efficient drug development and commercialization, with departments focused on research, clinical development, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- RLYB212: A monoclonal antibody targeting fetal FcRn to prevent alloimmune hemolytic disease of the fetus and newborn (HDFN). Currently in clinical trials. Market share is currently 0% as it's not yet commercialized. Competitors include pharmacological interventions to prevent alloimmunization with Rh immune globulin, as well as other biotech companies developing therapies for HDFN.
- RLYB211: Complement inhibitor C5. Market share is currently 0% as it's not yet commercialized. Competitors include companies such as Alexion Pharmaceuticals (acquired by AstraZeneca) that have developed complement inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high levels of innovation, risk, and regulation. The rare disease market is a growing segment within the industry, driven by increasing awareness, regulatory incentives, and advancements in diagnostics and therapeutics.
Positioning
Rallybio is positioned as a developer of therapies for rare diseases with high unmet medical needs. Its competitive advantage lies in its experienced management team, targeted approach to drug development, and focus on validated biological pathways.
Total Addressable Market (TAM)
The total addressable market for rare disease therapies is estimated to be over $200 billion. Rallybio is targeting specific sub-segments within this market, positioning itself to capture a share through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on validated biological pathways
- Strong intellectual property portfolio
- Targeting rare diseases with high unmet need
Weaknesses
- Reliance on successful clinical trial outcomes
- High cash burn rate
- Dependence on third-party manufacturing
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Expansion of pipeline through acquisitions or partnerships
- Regulatory approval and commercialization of lead products
- Increasing awareness and funding for rare disease research
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Difficulty in recruiting patients for clinical trials
Competitors and Market Share
Key Competitors
- AZN
- JNJ
- LLY
- GILD
Competitive Landscape
Rallybio faces competition from established pharmaceutical companies and other biotech firms developing therapies for rare diseases. Its advantage lies in its targeted approach and focus on validated pathways. But large pharma companies have extensive infrastructure, larger pipelines and significant financial war chests.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of its clinical pipeline and expansion of its research programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely depending on the perceived probability of success for its lead programs.
Recent Initiatives: Recent initiatives include advancing RLYB212 into later-stage clinical trials and expanding its research into new therapeutic areas.
Summary
Rallybio is a clinical-stage biotech company focused on rare diseases with an experienced team. Its success hinges on positive clinical trial results, particularly for its lead programs RLYB212 and RLYB211. It competes with larger, more established pharmaceutical companies. Key challenges include managing its cash burn rate and securing regulatory approvals. Its targeted approach and focus on validated pathways offer promise if the therapies work.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rallybio Corp. SEC Filings
- Rallybio Corp. Investor Relations
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biotechnology industry is inherently risky, and investment decisions should be made with careful consideration and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rallybio Corp
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2021-07-29 | Co-Founder, President, CEO & Director Dr. Stephen Uden M.B, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://www.rallybio.com |
Full time employees 20 | Website https://www.rallybio.com | ||
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.